Get the app
public
ios_share
OncoPharm
chevron_right
Enfortumab-vedotin (& Asciminib)
Dec 26, 2019
16:27
forum
Ask episode
play_arrow
Play
view_agenda
Chapters
auto_awesome
Transcript
info_circle
Episode notes
Closing out the year discussing FDA's approval of enfortumab-vedotin for urothelial cancer and a new, but pharmacologically unique, TKI with activity in CML (12:45). Happy New Year!
